Contrasting Lakewood-Amedex Biotherapeutics (LABT) and Its Peers

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) is one of 223 public companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its rivals? We will compare Lakewood-Amedex Biotherapeutics to related companies based on the strength of its earnings, risk, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Earnings & Valuation

This table compares Lakewood-Amedex Biotherapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lakewood-Amedex Biotherapeutics	N/A	N/A	-0.93
Lakewood-Amedex Biotherapeutics Competitors	$343.42 million	-$26.35 million	-5.50

Lakewood-Amedex Biotherapeutics’ rivals have higher revenue, but lower earnings than Lakewood-Amedex Biotherapeutics. Lakewood-Amedex Biotherapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Lakewood-Amedex Biotherapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakewood-Amedex Biotherapeutics	1	0	0	0	1.00
Lakewood-Amedex Biotherapeutics Competitors	2259	2433	4247	71	2.24

As a group, “Pharmaceutical Preparations” companies have a potential upside of 124.49%. Given Lakewood-Amedex Biotherapeutics’ rivals stronger consensus rating and higher probable upside, analysts plainly believe Lakewood-Amedex Biotherapeutics has less favorable growth aspects than its rivals.

Profitability

This table compares Lakewood-Amedex Biotherapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A
Lakewood-Amedex Biotherapeutics Competitors	-5,748.04%	-260.77%	-48.59%

Institutional and Insider Ownership

30.7% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 14.9% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Lakewood-Amedex Biotherapeutics rivals beat Lakewood-Amedex Biotherapeutics on 7 of the 11 factors compared.

About Lakewood-Amedex Biotherapeutics

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide. The rapid rise of resistant pathogens has rendered many existing antibiotics ineffective against these pathogens, increasing the risk of severe infections, prolonged hospital stays, and substantial economic burdens. Despite this urgent need, the development of new antibiotics has slowed, with most advancements occurring within existing drug classes, leaving these new compounds vulnerable to resistance mechanisms. Our product candidates consist of antimicrobials targeting acute and chronic infectious diseases, which are delivered locally to the site of infection. As of March 2026, we hold 68 issued and 36 pending patent applications for our products and technologies, with coverage in major pharmaceutical markets. We have successfully completed our first exploratory human clinical trials for our lead product, the broad-spectrum Bisphosphocin® (anti-bacterial) Nu-3, which is being developed for the topical treatment of mildly infected diabetic foot ulcers (iDFU). We plan to conduct an initial Phase 2a safety and dose response study, followed by a placebo-controlled Phase 2b dose comparative study to identify the optimal dose for Phase 3 trials and eventual commercialization. This study will also determine the most appropriate administration regimen for Nu-3 gel formation in mildly infected diabetic foot ulcers. Additionally, we are advancing early-stage pipeline compounds and are focused on further characterizing them to identify the best clinical indications for non-clinical and clinical evaluation. Advancement of any of our product candidates to the commercialization stage is completely dependent on the outcome of clinical studies that are reviewed and approved by the FDA or other comparable regulatory authorities. Headquartered in University Park, Florida, we were originally incorporated in Delaware on July 11, 2006, under the name Nu Pharmas, Inc. (“Nu Pharmas”). We initially focused on antisense RNA research and the contract manufacturing of oligonucleotides. On April 9, 2007, Nu Pharmas acquired substantially all the assets of Renaissance Nutraceuticals, Inc., a Delaware corporation, and subsequently changed its name to Amedex Therapeutics, Inc. (“Amedex Therapeutics”). On November 11, 2007, Amedex Therapeutics acquired substantially all the assets of Lakewood Pharmaceuticals, Inc., a Delaware corporation. On February 1, 2008, Amedex Therapeutics changed its name to Lakewood-Amedex Inc. On June 5, 2025, the Company changed its name to Lakewood-Amedex Biotherapeutics Inc. and redomiciled as a Nevada corporation. Our corporate address is in University Park, Florida.